Rhumbline Advisers Boosts Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Rhumbline Advisers increased its stake in Vaxcyte, Inc. by 5.5%, owning approximately 181,230 shares after acquiring an additional 9,416 shares in the first quarter.
• The stock opened at $32.17, with Vaxcyte having a market capitalization of $4.18 billion and a P/E ratio of -7.83, while its shares have fluctuated between a 52-week low of $27.66 and a high of $121.06.
• Analysts have mixed ratings for Vaxcyte, with a new target price from Goldman Sachs of $38.00, while Cowen maintains a "buy" rating with an average target price of $106.25.

Rhumbline Advisers boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 181,230 shares of the company's stock after purchasing an additional 9,416 shares during the period. Rhumbline Advisers owned about 0.14% of Vaxcyte worth $6,843,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Strs Ohio bought a new stake in Vaxcyte in the 1st quarter worth about $627,000. Intech Investment Management LLC grew its position in Vaxcyte by 44.3% in the 1st quarter. Intech Investment Management LLC now owns 89,212 shares of the company's stock worth $3,369,000 after purchasing an additional 27,384 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Vaxcyte by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock valued at $19,409,000 after acquiring an additional 41,034 shares during the period. Caxton Associates LLP bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $226,000. Finally, Jones Financial Companies Lllp grew its position in shares of Vaxcyte by 113,702.7% during the 1st quarter. Jones Financial Companies Lllp now owns 166,152 shares of the company's stock valued at $6,274,000 after acquiring an additional 166,006 shares during the period. 96.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PCVX. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday. They set a "neutral" rating and a $38.00 target price for the company. Cowen reissued a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Vaxcyte presently has a consensus rating of "Buy" and an average target price of $106.25.

Vaxcyte Trading Down 3.6%

Shares of PCVX stock traded down $1.17 during trading on Monday, reaching $31.00. 1,260,839 shares of the company's stock traded hands, compared to its average volume of 1,422,392. The company has a market capitalization of $4.02 billion, a P/E ratio of -7.54 and a beta of 1.04. The firm's 50-day moving average is $33.14 and its 200 day moving average is $38.47. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the prior year, the firm posted ($1.10) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.